durapatite has been researched along with Carcinoma 256, Walker in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, D; Hu, P; Tian, Y; Xia, Q; Zhang, J | 1 |
| Breuer, E; Golomb, G; Klenner, T; Krempien, B; Mönkkönen, J; Ornoy, A; Patlas, N; Schlossman, A; Similä, J; Stadler, H; Van Gelder, JM | 1 |
| Alferiev, IS; Breuer, E; Cohen, H; Ezra, A; Golomb, G; Hägele, G; Hoffman, A; Mönkkönen, J; Ornoy, A; Patlas, N; Pinto, T; Sagi, H; Seibel, MJ; Solomon, V; Stepensky, D | 1 |
3 other study(ies) available for durapatite and Carcinoma 256, Walker
| Article | Year |
|---|---|
DNA damage effects of hydroxyapatite ultrofine powder on W-256 sarcoma cells and lymphocytes in rats.
Topics: Animals; Antineoplastic Agents; Carcinoma 256, Walker; Comet Assay; DNA Damage; DNA, Neoplasm; Durapatite; Female; Lymphocytes; Powders; Rats; Rats, Wistar | 1999 |
In vitro and in vivo effects of tetrakisphosphonates on bone resorption, tumor osteolysis, ectopic calcification, and macrophages.
Topics: Animals; Bioprosthesis; Bone Resorption; Calcinosis; Carcinoma 256, Walker; Cell Line; Cell Survival; Diphosphonates; Durapatite; Etidronic Acid; Female; Macrophages; Mice; Osteolysis; Pamidronate; Rats; Rats, Wistar | 1997 |
Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate.
Topics: Administration, Oral; Alendronate; Animals; Antineoplastic Agents; Betaine; Bone Diseases; Bone Neoplasms; Calcium; Capsules; Carcinoma 256, Walker; Cell Line; Diphosphonates; Diuretics, Osmotic; Durapatite; Injections, Intravenous; Intestinal Absorption; Macrophages; Male; Mannitol; Osteogenesis; Pamidronate; Rats; Rats, Inbred Strains; Tight Junctions; Tissue Distribution | 1999 |